Silver sulfadiazine in modern dermatology
DOI:
https://doi.org/10.25251/9wwnjf59Keywords:
antimicrobial, burns, dermatology, silver, sulfadiazine, topical, woundAbstract
Silver sulfadiazine, a topical antimicrobial that releases silver ions to disrupt bacterial cell membranes, is primarily used for second- and third-degree burns owing to its broad-spectrum activity against bacteria, fungi, and certain viruses. Beyond burns, silver sulfadiazine can be used off-label for conditions such as diabetic and pressure ulcers, atopic dermatitis, and radiation dermatitis. The literature suggests it may reduce bacterial load, accelerate healing, and address challenges such as multidrug-resistant Staphylococcus aureus. Rare side effects, including localized reactions and systemic toxicity with extensive use, necessitate cautious application, especially in vulnerable populations. Despite these limitations, silver sulfadiazine remains a cornerstone of dermatological wound care. Continued research is needed to optimize its use alongside emerging therapies.
References
1. Salle R, Del Giudice P, Skayem C, Hua C, Chosidow O. Secondary Bacterial Infections in Patients with Atopic Dermatitis or Other Common Dermatoses. Am J Clin Dermatol. 2024;25:623–37. [PMID: 38578398].
2. Alipour J, Mehdipour Y, Karimi A. Epidemiology and outcome analysis of 3030 burn patients with an ICD-10 approach. Ann Burns Fire Disasters. 2020;33:3–13. [PMID: 32523489].
3. Kucan JO, Robson MC, Heggers JP, Ko F. Comparison of silver sulfadiazine, povidone-iodine and physiologic saline in the treatment of chronic pressure ulcers. J Am Geriatr Soc. 1981;29:232–5. [PMID: 7014694].
4. Mohan M, Gupta SK, Kalra VK, Vajpayee RB, Sachdev MS. Topical silver sulphadiazine--a new drug for ocular keratomycosis. Br J Ophthalmol. 1988;72:192–5. [PMID: 3281706].
5. Modak SM, Sampath L, Fox CL Jr. Combined topical use of silver sulfadiazine and antibiotics as a possible solution to bacterial resistance in burn wounds. J Burn Care Rehabil. 1988;9:359–63. [PMID: 3146573].
6. Durán N, Durán M, de Jesus MB, et al. Silver nanoparticles: A new view on mechanistic aspects on antimicrobial activity. Nanomedicine. 2016;12:789–99. [PMID: 26724539].
7. Gallagher JJ, Williams-Bouyer N, Villarreal C, Heggers JP, Herndon DN. Treatment of infection in burns. In: Total Burn Care. Herndon DN, editor. Elsevier; 2007. p. 136–76.
8. Oaks RJ, Cindass R. Silver sulfadiazine. In: StatPearls. StatPearls Publishing; 2025.
9. [No title]. n.d. https://labeling.pfizer.com/showlabeling.aspx?id=701 (accessed 3 February 2025).
10. Aoyama H, Yokoo K, Fujii K. Systemic absorption of sulphadiazine, silver sulphadiazine and sodium sulphadiazine through human burn wounds. Burns. 1990;16:163–5. [PMID: 2383353].
11. Hummel RP, MacMillan BG, Altemeier WA. Topical and systemic antibacterial agents in the treatment of burns. Ann Surg. 1970;172:370–84. [PMID: 5459095].
12. Hoeksema H, Vandekerckhove D, Verbelen J, Heyneman A, Monstrey S. A comparative study of 1% silver sulphadiazine (Flammazine®) versus an enzyme alginogel (Flaminal®) in the treatment of partial thickness burns. Burns. 2013;39:1234–41. [PMID: 23523226].
13. Shahzad MN, Ahmed N. Effectiveness of Aloe Vera gel compared with 1% silver sulphadiazine cream as burn wound dressing in second degree burns. J Pak Med Assoc. 2013;63:225–30. [PMID: 23894900].
14. Aziz Z, Abdul Rasool Hassan B. The effects of honey compared to silver sulfadiazine for the treatment of burns: A systematic review of randomized controlled trials. Burns. 2017;43:50–7. [PMID: 27576926].
15. Di Domenico EG, De Angelis B, Cavallo I, et al. Silver Sulfadiazine Eradicates Antibiotic-Tolerant Staphylococcus aureus and Pseudomonas aeruginosa Biofilms in Patients with Infected Diabetic Foot Ulcers. J Clin Med Res. 2020;9. [PMID: 33255545].
16. Lindsay S, Oates A, Bourdillon K. The detrimental impact of extracellular bacterial proteases on wound healing. Int Wound J. 2017;14:1237–47. [PMID: 28745010].
17. Robson MC, Heggers JP. Bacterial quantification of open wounds. Mil Med. 1969;134:19–24. [PMID: 4990704].
18. Ouvry PA. [A trial of silver sulfadiazine in the local treatment of venous ulcer]. Phlebologie. 1989;42:673–9. [PMID: 2626487].
19. Miller AC, Rashid RM, Falzon L, Elamin EM, Zehtabchi S. Silver sulfadiazine for the treatment of partial-thickness burns and venous stasis ulcers. J Am Acad Dermatol. 2012;66:e159–65. [PMID: 20724028].
20. Hemati S, Asnaashari O, Sarvizadeh M, et al. Topical silver sulfadiazine for the prevention of acute dermatitis during irradiation for breast cancer. Support Care Cancer. 2012;20:1613–8. [PMID: 22006502].
21. Blicharz L, Rudnicka L, Samochocki Z. Staphylococcus aureus: an underestimated factor in the pathogenesis of atopic dermatitis? Postepy Dermatol Alergol. 2019;36:11–7. [PMID: 30858773].
22. Rangel SM, Paller AS. Bacterial colonization, overgrowth, and superinfection in atopic dermatitis. Clin Dermatol. 2018;36:641–7. [PMID: 30217276].
23. Ogonowska P, Gilaberte Y, Barańska-Rybak W, Nakonieczna J. Colonization With Staphylococcus aureus in Atopic Dermatitis Patients: Attempts to Reveal the Unknown. Front Microbiol. 2020;11:567090. [PMID: 33505363].
24. Antonov NK, Garzon MC, Morel KD, et al. High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pediatric population. Antimicrob Agents Chemother. 2015;59:3350–6. [PMID: 25824213].
25. Pruskowski KA, Mitchell TA, Kiley JL, et al. Diagnosis and management of invasive fungal wound infections in burn patients. European Burn Journal. 2021;2:168–83. [DOI: 10.3390/ebj2040013].
26. Ciloglu NS, Mert AI, Doğan Z, et al. Efficacy of Silver-Loaded Nanofiber Dressings in Candida albicans–Contaminated Full-Skin Thickness Rat Burn Wounds. J Burn Care Res. 2014;35:e317–20. [PMID: 25118002].
27. Qureshi UA, Ahmed N. Type V aplasia cutis congenita. Ann Saudi Med. 2010;30:171–2. [PMID: 20220274].
28. Perry BM, Maughan CB, Crosby MS, Hadenfeld SD. Aplasia cutis congenita type V: a case report and review of the literature. Int J Dermatol. 2017;56:e118–21. [PMID: 28480995].
29. Silva Díaz E, Molini Menchón MO, Estébanez Corrales A, et al. Type V aplasia cutis congenita in a preterm newborn successfully resolved. Dermatol Ther. 2020;33:e13888. [PMID: 32567088].
30. Rakowska PD, Tiddia M, Faruqui N, et al. Antiviral surfaces and coatings and their mechanisms of action. Commun Mater. 2021;2:1–19. [DOI: 10.1038/s43246-021-00153-y].
31. Chang T-W, Weinstein L. In vitro activity of silver sulfadiazine against Herpesvirus hominis. J Infect Dis. 1975;132:79–81. [PMID: 168275].
32. Montes LF, Muchinik G, Fox CL Jr. Response of varicella zoster virus and herpes zoster to silver sulfadiazine. Cutis. 1986;38:363–5. [PMID: 3026736].
33. Salisbury A-M, Chen R, Mullin M, Foulkes L, Percival SL. In vitro evaluation of resistance development to silver sulfadiazine and subsequent cross-resistance to antibiotics. Surg Technol Int. 2022;40:55–60. [PMID: 35130350].
34. Szabo MM, Urich MA, Duncan CL, Aballay AM. Patient adherence to burn care: A systematic review of the literature. Burns. 2016;42:484–91. [PMID: 26777450].
35. Warriner R, Burrell R. Infection and the chronic wound: a focus on silver. Adv Skin Wound Care. 2005;18 Suppl 1:2–12. [PMID: 16220035].
36. Pletts MW, Burrell RE. Clinically relevant evaluation of the antimicrobial and anti-inflammatory properties of nanocrystalline and nanomolecular silver. Wound Repair Regen. 2025;33:e13249. [PMID: 39707715].
37. Maghsoudi H, Monshizadeh S, Mesgari M. A comparative study of the burn wound healing properties of saline-soaked dressing and silver sulfadiazine in rats. Indian J Surg. 2011;73:24–7. [PMID: 22211033].
38. Willis MS, Cairns BA, Purdy A, et al. Persistent lactic acidosis after chronic topical application of silver sulfadiazine in a pediatric burn patient: a review of the literature. Int J Burns Trauma. 2013;3:1–8. [PMID: 23386980].
39. Thomson PD, Moore NP, Rice TL, Prasad JK. Leukopenia in acute thermal injury: evidence against topical silver sulfadiazine as the causative agent. J Burn Care Rehabil. 1989;10:418–20. [PMID: 2793919].
40. Wright AA, Vesta KS, Stark JE, Smith WJ. Stevens-Johnson syndrome associated with furosemide: a case report: A case report. J Pharm Pract. 2010;23:367–70. [PMID: 21507837].
41. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.e1–13; quiz 185–6. [PMID: 23866878].
42. Thyagarajan B, Deshpande SS. Cotrimoxazole and neonatal kernicterus: a review. Drug Chem Toxicol. 2014;37:121–9. [PMID: 24099411].
43. Eldad A, Neuman A, Weinberg A, et al. Silver sulphadiazine-induced haemolytic anaemia in a glucose-6-phosphate dehydrogenase-deficient burn patient. Burns. 1991;17:430–2. [PMID: 1760119].
44. Muller MJ, Hollyoak MA, Moaveni Z, et al. Retardation of wound healing by silver sulfadiazine is reversed by Aloe vera and nystatin. Burns. 2003;29:834–6. [PMID: 14636760].
45. Kjolseth D, Frank JM, Barker JH, et al. Comparison of the effects of commonly used wound agents on epithelialization and neovascularization. J Am Coll Surg. 1994;179:305–12. [PMID: 7520807].
46. Shivanna V, Dasegowda V. Comparison of Disk Diffusion and Agar Dilution Method for the Detection of Mupirocin Resistance in Staphylococcal Isolates from Skin and Soft Tissue Infections. J Lab Physicians. 2023;15:372–6. [PMID: 37564234].
47. Pona A, Quan EY, Cline A, Feldman SR. Review of the use of gentian violet in dermatology practice. Dermatol Online J. 2020;26. [DOI: 10.5070/D3265048772].
48. Tsang K-K, Kwong EW-Y, To TS-S, Chung JW-Y, Wong TK-S. A pilot randomized, controlled study of nanocrystalline silver, Manuka honey, and conventional dressing in healing diabetic foot ulcer. Evid Based Complement Alternat Med. 2017;2017:5294890. [PMID: 28239398].
49. Zhao M, Zhang D, Tan L, Huang H. Silver dressings for the healing of venous leg ulcer: A meta-analysis and systematic review: A meta-analysis and systematic review. Medicine (Baltimore). 2020;99:e22164. [PMID: 32925780].
50. Tsai C-H, Hsu H-C, Lin C-J. Treatment of chronic wounds with the silver-containing activated carbon fiber dressing: Three cases. J Med Cases. 2014;5:587–91. [DOI: 10.14740/jmc1960w].
51. Nherera LM, Trueman P, Roberts CD, Berg L. A systematic review and meta-analysis of clinical outcomes associated with nanocrystalline silver use compared to alternative silver delivery systems in the management of superficial and deep partial thickness burns. Burns. 2017;43:939–48. [PMID: 28161149].
52. Cartotto R. Topical antimicrobial agents for pediatric burns. Burns Trauma. 2017;5:33. [PMID: 29075650].
53. Lepelletier D, Maillard JY, Pozzetto B, Simon A. Povidone iodine: Properties, mechanisms of action, and role in infection control and Staphylococcus aureus decolonization. Antimicrob Agents Chemother. 2020;64. [PMID: 32571829].
54. Homann H-H, Rosbach O, Moll W, et al. A liposome hydrogel with polyvinyl-pyrrolidone iodine in the local treatment of partial-thickness burn wounds. Ann Plast Surg. 2007;59:423–7. [PMID: 17901735].
55. Yüksel EB, Yıldırım AM, Bal A, Kuloglu T. The effect of different topical agents (silver sulfadiazine, povidone-iodine, and sodium chloride 0.9%) on burn injuries in rats. Plast Surg Int. 2014;2014:907082. [PMID: 25328700].
56. Silver Sulfadiazine Cream Rx, 400 g. Agtech Inc. n.d. https://store.agtechinc.com/products/silver-sulfadiazine-cream-rx-400-g (accessed 17 August 2024).
57. Mupirocin topical prices, coupons, copay cards & patient assistance. Drugs.com. n.d. https://www.drugs.com/price-guide/mupirocin-topical (accessed 17 August 2024).
58. Sulfadiazine. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
59. Poznański J, Sołdacki D, Czarkowska-Pączek B, et al. Cirrhotic liver of liver transplant recipients accumulate silver and co-accumulate copper. Int J Mol Sci. 2021;22:1782. [PMID: 33670100].
60. Iwasaki S, Yoshimura A, Ideura T, Koshikawa S, Sudo M. Elimination study of silver in a hemodialyzed burn patient treated with silver sulfadiazine cream. Am J Kidney Dis. 1997;30:287–90. [PMID: 9261044].
61. Kulick MI, Wong R, Okarma TB, Falces E, Berkowitz RL. Prospective study of side effects associated with the use of silver sulfadiazine in severely burned patients. Ann Plast Surg. 1985;14:407–19. [PMID: 4083697].
62. Fuller FW. The side effects of silver sulfadiazine. J Burn Care Res. 2009;30:464–70. [PMID: 19349889].
63. Pinnock TM, Volcheck GW, Smith MM, et al. Réactions anaphylactiques périopératoires aux cathéters veineux centraux et cathéters de l’artère pulmonaire contenant de la chlorhexidine, de la sulfadiazine ou du latex : une étude de cohorte historique. Can J Anaesth. 2023;70:824–35. [PMID: 36829103].
64. Levin NJ, Erben Y, Li Y, Brigham TJ, Bruce AJ. A systematic review and meta-analysis comparing burn healing outcomes between silver sulfadiazine and Aloe vera. Cureus. 2022;14:e30815. [PMID: 36337821].
65. Norman G, Westby MJ, Rithalia AD, et al. Dressings and topical agents for treating venous leg ulcers. Cochrane Database Syst Rev. 2018;6:CD012583. [PMID: 29906322].
66. Tchernev G, Zanardelli M, Voicu C, et al. Impetiginized dyshidrotic eczema. Open Access Maced J Med Sci. 2017;5:539–40. [PMID: 28785355].
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Natalia Chalupczak, Jessica Q. Duong, Joseph Jorizzo, Steven R. Feldman (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
